As more biotech companies use RWE to support approvals, broader real-world outcomes for their products will emerge.
While randomised clinical trials (RCTs) remain the standard for evidence generation, real-world evidence (RWE) serves as a disrupter, bringing greater efficiency to the development life cycle and novel ways to improve regulatory decision-making - ultimately maximising revenue.
At the same time, the evidence produced by collecting, standardising and analysing real world data (RWD), which then informs RWE, has a purpose across an array of research applications. In the European Union and United States markets, it is being used in myriad ways, from continuous monitoring and drug utilisation studies to routine safety monitoring and filling evidentiary gaps.
With a variety of RWD sources available - such as electronic health records (EHRs) - and innovative services to gather, process and analyse them, RWE sourced from RWD is rapidly becoming the latest frontier for companies to build a competitive advantage through faster and more efficient access to this type of information and insights. The recent uptick in the use of RWE can be attributed to the following:
- Greater availability of and access to RWD
- Ability for it to influence decision-making across the product life cycle
- Continued focus on the development of guidelines for its standardised use
- Growing payer interest in using it to support a product’s value story
Due to the dynamic nature of the biotech market, new complex research needs will rise as more data become available and technology brings innovative ways to process and use collected data. These complexities that exist across the business spectrum, whether it’s scientific, operational, regulatory or market access, need to be accounted for in the development of a successful research and commercialisation plan.
It’s within this context, that biotechs will need to develop a comprehensive RWE strategy to maximise revenue in biotech trials.
Regulatory appeal
Already, there are several instances from therapeutic areas - including oncology and immunotherapy, to medical devices and diagnostics - where the US Food & Drug Administration (FDA) has accepted RWE instead of data from a control arm through a traditional RCT.
The FDA has been receptive to examining historical, real-world cohorts of patients treated under the standard of care for safety and efficacy data, particularly where a control arm is not possible. As more success is achieved in these cases, the FDA will most likely continue accepting RWE as an asset in regulatory decision-making. For example, in 2018, the FDA unveiled its own MyStudies app for the collection of RWD, to continue to drive the use of RWE moving forward. This app enables developers to advance new ways to access and use data collected directly from patients, with the necessary controls in place to ensure patient privacy.
Maximising RWE
Technology advancements such as artificial intelligence, machine learning and natural language processing, can increase RWE output, decrease time to actionable insights, and take advantage of the vast data sources available.
Also, insights gained from existing data, or as a by-product of clinical care, can improve clinical trial efficiency by (1) streamlining clinical trial recruitment, (2) supporting regulatory filings, (3) expanding patient access, and (4) being used for drug safety surveillance. With the right technology, infrastructure and support, RWD can be collected, stored, analysed and reported, bringing the benefits of RWE to clinical research and commercialisation decision-making.
While RWE can be useful on its own, it can also serve as a tool to inform and supplement traditional clinical trials in protocol feasibility assessment, site/physician identification, patient identification, and historical controls.
Using RWE in this manner provides - in some cases - the only feasible option, in addition to delivering cost and speed benefits versus a prospective controlled study. Enhancing feasibility and patient recruitment through RWD analyses, as well as using readily accessible RWD for emerging research applications, are just the beginning of where RWE and clinical research can merge for more effective and efficient delivery of research objectives. Innovative ways of converging the two, through RCTs conducted within a real-world setting, also known as pragmatic trials, will continue to advance.
For instance, RWD can cut time and costs in enrolment processes, which can consume nearly 40 percent of a clinical trial budget. Through a protocol feasibility assessment, researchers can use RWD to estimate the size of an available patient population based on the defined inclusion/exclusion criteria. That criterion can be applied against de-identified patient data from providers’ EHR systems to determine eligible patients by provider, allowing sponsors to focus on sites that serve a population aligned with the protocol. Software can be programmed at those sites to alert physicians to suitable patients within their practices, giving providers the opportunity to easily consent and enrol prospective participants.
To capitalise on computing advancements, biotech companies should adopt an RWE technology platform that incorporates smart data processing, analysis and outcomes. When this platform is integrated into an overall comprehensive RWE strategy, new digital disruption innovations can enhance efficiency in drug development, improve patient enrolment and retention, drive new business and maximise revenue.
Deploying a RWE strategy
By identifying what evidence is needed to support regulators’ and payers’ decision-making, biotechs can develop an evidence generation plan across a product’s life cycle to leverage outputs and identify any existing data gaps. As more biotech companies use RWE to support approvals and monitor real-world performance of their products, broader real-world outcomes for their products will emerge. As a result, biotechs will accumulate an abundance of data that will need to be strategically synthesised and analysed.
For successful RWE deployment and enhanced revenue, biotechs should:
- Develop a plan early in the product lifecycle and revisit it at key milestones
- Build an integrated, cross-functional team with the necessary expertise to ensure RWD is applied at all appropriate steps
- Identify expected evidence gaps in advance, and fill them with a combination of primary or secondary RWD-derived evidence
A strategic plan requires flexibility and focus on high priority research objectives and platform scalability and architecture. Cloud-based systems that can combine disparate RWD assets into a single repository and provide analytics that can support teams working across the product lifecycle can serve as a centralised environment for all of the biotech’s RWD assets, breaking down any potential ‘data silos.’ This way, each audience across the enterprise has the capacity to run analysis on the right data sets that are specific to their purpose. As more RWE is generated within the biotech industry, its insights will have a great impact on informing stakeholders - whether its manufacturers, regulators, clinicians, patients, or payers. Having a strategic plan in place will be necessary to maximise revenue.
Real World Data insights
ICON's real world data (RWD) continues to drive healthcare and research discussions and decisions. Stay up to date with the latest information that regulators, payers and providers demand.
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel